Third-party tested for purity
Not for human consumption
Secure & discreet delivery
99%+ Purity Guaranteed
$125.00 Original price was: $125.00.$100.00Current price is: $100.00.
Retatrutide remains investigational and has not yet been approved by regulatory agencies. Phase 3 topline announcements are also not a substitute for complete peer-reviewed publications and regulatory review. Products sold online claiming to contain retatrutide should not be treated as equivalent to the investigational medicine used in controlled clinical trials.
Evidence note: Phase 2 human data are published; positive Phase 3 topline results were reported in 2026. Retatrutide remains investigational.

Retatrutide is an investigational peptide-based medication that activates three hormone receptors: GIP, GLP-1 and glucagon. This triple-receptor design separates it from single- and dual-receptor incretin therapies and has made it a major focus of obesity and metabolic research.
| ✓ Body-Weight Research | Clinical trials have investigated substantial changes in body weight in adults with obesity or overweight. |
| ✓ GLP-1 Activity | Targets the GLP-1 receptor, which plays a role in appetite, glucose regulation and energy intake. |
| ✓ GIP Activity | Also activates the GIP receptor, adding a second incretin pathway to the research profile. |
| ✓ Glucagon Activity | Studies are examining glucagon-receptor activity and its potential contribution to energy expenditure and metabolic effects. |
| ✓ Glycemic Measures | Clinical studies have examined A1C, fasting glucose, insulin and related cardiometabolic markers. |
| ✓ Cardiometabolic Research | Large clinical programs are evaluating obesity and associated metabolic complications. |
Unlike many peptides discussed online, retatrutide has undergone evaluation in randomized human clinical trials. A published Phase 2 obesity trial found dose-dependent reductions in body weight over 48 weeks and also examined waist circumference, glucose regulation, insulin, lipids and blood pressure. Gastrointestinal adverse events were the most common, and the trial also reported dose-dependent increases in heart rate. In 2026, the developer reported positive topline results from multiple Phase 3 TRIUMPH studies, including studies in adults with obesity, type 2 diabetes and cardiovascular disease.
Not for human consumption. For laboratory research purposes only.
We provide a Certificate of Analysis for every batch.
Purity and identity verified by independent laboratory testing.
Every batch is third-party tested for purity and identity.
Products are for laboratory research purposes only.
All orders are shipped discreetly and securely.
99%+ purity guaranteed on all peptide products.
🇨🇦 Made in Canada · 🧪 Lab tested
WELCOME OFFER
Join the Peptides Plus newsletter for new releases and restock alerts. Your one-time code arrives by email straight away.
One use, valid for 30 days. No spam – unsubscribe anytime. See our Privacy Policy.